Market Closed - Australian S.E. 11:18:27 2024-04-28 pm EDT 5-day change 1st Jan Change
0.032 AUD +14.29% Intraday chart for InhaleRx Limited +14.29% +10.34%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
InhaleRx Limited announced that it expects to receive AUD 0.5 million in funding from Peak Asset Management, LLC CI
InhaleRx Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
InhaleRx to Focus on Breakthrough Cancer Pain for Phase 2 Trial of Cannabinoid Analgesic MT
InhaleRx Secures Nearly AU$550,000 R&D tax Incentive Prepayment MT
InhaleRX Completes Phase One Trial for Pain Medication Device MT
InhaleRx Files Ethics Application for Panic Disorder Trial MT
InhaleRx Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
InhaleRx Limited Announces Change of Registered Office Address CI
InhaleRx Limited Announces Executive Changes CI
InhaleRx Completes First Cohort of Phase One Clinical Trial MT
Australian Shares Retreat Anew on Rate Hike, Slower-than-Expected GDP Growth MT
InhaleRx Doses First Individuals for Phase One Trial of Inhalable Pain Medication MT
InhaleRx Limited Auditor Raises 'Going Concern' Doubt CI
InhaleRx Limited Reports Earnings Results for the Full Year Ended December 31, 2022 CI
InhaleRx Hires Contract Research Organization for Upcoming Clinical Trials MT
Inhalerx Limited Announces Fda Pre-Ind Application Update CI
InhaleRx Limited Announces Board and Management Changes CI
InhaleRx Limited Announces the Appointment of Darryl Davies as Chief Executive Officer CI
InhaleRx Raises $810,000 From Share Placement MT
InhaleRx Limited Reports Earnings Results for the Half Year Ended June 30, 2022 CI
InhaleRx Limited Auditor Raises 'Going Concern' Doubt CI
InhaleRx Secures Licenses to Sell, Supply Controlled Substances MT
Victorian Department of Health & Human Services Grants Wholesale Licenses to Inhalerx Limited to Sell and Supply Poisons or Controlled Substances CI
InhaleRx Limited Reports Earnings Results for the Full Year Ended December 31, 2021 CI
InhaleRx Ltd Appoints Darryl Davies as Executive Director CI
Chart InhaleRx Limited
More charts
Inhalerx Limited is an Australia-based healthcare company. The Company is focused on developing medicinal drug-device products to address unmet medical needs in the pain management and mental health sectors. The Company partners with educators in their technical and therapeutic fields, to provide inhalation therapies that deliver added value for patients, doctors, business partners, governments, and stakeholders alike. Its Medihale Inhaler is a sealed pod inhaler designed specifically for use with inhaled formulations. It utilizes heat (not burn) technology, avoiding the production of pyrolytic toxins and carcinogenic often created when combusting plant material. The sealed tamper-proof Medihale Pods provide patients with additional security. The Medihale Protective Charging Case automatically recharges the Medihale Inhaler when the inhaler is returned to its case. The Medihale Protective Charging Case even has a dedicated storage space to carry an extra Medihale c-liquid Pod.
More about the company
  1. Stock Market
  2. Equities
  3. IRX Stock
  4. News InhaleRx Limited
  5. InhaleRx Secures Nearly AU$550,000 R&D tax Incentive Prepayment